Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Receivables (2020 - 2025)

Gain Therapeutics (GANX) has 5 years of Receivables data on record, last reported at $917094.0 in Q3 2025.

  • For Q3 2025, Receivables changed N/A year-over-year to $917094.0; the TTM value through Sep 2025 reached $917094.0, changed N/A, while the annual FY2024 figure was $494684.0, N/A changed from the prior year.
  • Receivables reached $917094.0 in Q3 2025 per GANX's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Receivables topped out at $1.5 million in Q2 2025 and bottomed at $4486.0 in Q1 2021.
  • Average Receivables over 4 years is $464515.7, with a median of $353166.0 recorded in 2021.
  • Peak YoY movement for Receivables: surged 1815.35% in 2021, then plummeted 46.6% in 2022.
  • A 4-year view of Receivables shows it stood at $163724.0 in 2021, then plummeted by 46.6% to $87430.0 in 2022, then surged by 465.81% to $494684.0 in 2024, then skyrocketed by 85.39% to $917094.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $917094.0 in Q3 2025, $1.5 million in Q2 2025, and $638961.0 in Q1 2025.